Search

Your search keyword '"N, Fukuhara"' showing total 18 results

Search Constraints

Start Over You searched for: Author "N, Fukuhara" Remove constraint Author: "N, Fukuhara" Journal international journal of hematology Remove constraint Journal: international journal of hematology
18 results on '"N, Fukuhara"'

Search Results

2. Japanese phase Ib study of the oral PI3K-δ and -γ inhibitor duvelisib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma.

3. Measurable residual disease in Japanese patients with relapsed or refractory chronic lymphocytic leukemia treated with venetoclax.

4. Long-term safety profile of tirabrutinib: final results of a Japanese Phase I study in patients with relapsed or refractory B-cell malignancies.

5. Efficacy and safety of tisagenlecleucel in adult Japanese patients with relapsed or refractory follicular lymphoma: results from the phase 2 ELARA trial.

6. Safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study.

7. Efficacy and safety of modified BLd therapy for Japanese patients with transplant-ineligible multiple myeloma.

8. Unrelated cord blood transplantation for adult-onset EBV-associated T-cell and NK-cell lymphoproliferative disorders.

9. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

10. Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data.

11. Extranasal extranodal NK/T-cell lymphoma associated with systemic lupus erythematosus.

12. Successful treatment of methotrexate-associated classical Hodgkin lymphoma with brentuximab vedotin-combined chemotherapy: a case series.

13. Analysis of Japanese patients from the AUGMENT phase III study of lenalidomide + rituximab (R 2 ) vs. rituximab + placebo in relapsed/refractory indolent non-Hodgkin lymphoma.

14. Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies: final analysis of phase I study.

15. Bendamustine plus rituximab for previously untreated patients with indolent B-cell non-Hodgkin lymphoma or mantle cell lymphoma: a multicenter Phase II clinical trial in Japan.

17. Inhibition of human primary megakaryocyte differentiation by anagrelide: a gene expression profiling analysis.

18. Identification of a novel putative mitochondrial protein FAM210B associated with erythroid differentiation.

Catalog

Books, media, physical & digital resources